CERT

Certara, Inc.

Certara, Inc.CERT

Healthcare · Health Information Services

8.89USD

+2.89%

Sep 25, 2026

CERT overview ready

Specialized provider of model-informed drug development and regulatory biosimulation

Certara is a specialized software-and-services enabler and near-pure-play supplier of model-informed drug-development workflows, spanning PBPK, QSP, pharmacometrics, clinical intelligence, and regulatory-grade biosimulation.

Narrative not measured

Computational Drug DevelopmentModel-Informed Drug Development and Regulatory BiosimulationPure play

Price action is under distribution

Longer-term context reads early recovery, with a near-term setup of daily advance.

Fair valuation

The price broadly reflects how much growth and cash flow it delivers per turn of revenue multiple, with upside and risk reasonably balanced.

Solid fundamentals

Free cash flow yield is strong.

Primary risk

Dependence on pharmaceutical R&D budgets.

Market Sep 24Filing Jun 30Price action Sep 24Research Sep 15

Conviction Level

Price

Loading price history…

Price Action

Price action is under distribution

Longer-term context reads early recovery, with a near-term setup of daily advance.

EntryReset + recovery

The stock is still rebuilding below its long-term weekly base, and the recent reset toward the daily SMA200 aligned with support at the weekly EMA21. Daily structure is recovering above the fast averages, improving the current entry location.

Key Financials

Market Cap: $1.4B
Avg Volume (60D): 3.0M
Revenue Growth YoY: +8.7%
Gross Margin: +48.5%
Operating Margin: +0.6%
Free Cash Flow Yield: +5.9%
Distance from 200DMA: +23.9%
Next Earnings: 2026-11-05
P/E: N/M
EV / EBITDA: 18.6x
EV / Sales: 3.5x

Market metrics as of Sep 24, 2026

Financial results for the period ended Jun 30, 2026

Filed balance-sheet data as of Jun 30, 2026

Fundamentals & Valuation

All three valuation perspectives agree this company is fair.

Certara, Inc. has a Fair valuation stance because the price broadly reflects how much growth and cash flow it delivers per turn of revenue multiple, with upside and risk reasonably balanced.

Company Research

Thesis

Opportunity

Moderate opportunity

Pharmaceutical and biotechnology investment in computational modeling, simulation, and validated evidence workflows to improve drug-program decisions, trial design, dose selection, safety assessment, and regulatory submissions.

Key risk

Dependence on pharmaceutical R&D budgets.

Narrative & Theme

Computational Drug Development

Part of Model-Informed Drug Development and Regulatory Biosimulation, with strong fit.

CERT has a genuine, direct exposure to a distinct drug-development infrastructure story that is not represented in the promoted narratives.

Narrative HeatUnavailable

Theme HeatNeutral6.7 / 10

This is the company’s own research reading. The canonical heat measurement for this story has not run.

Business & Markets

Healthcare · Health Information Services

What they do

Certara, Inc. provides technology-driven biosimulation services and software products to support drug discovery, preclinical and clinical research, regulatory submissions, and market access globally.

How it earns

The company generates revenue primarily through subscription and project-based services related to its biosimulation platforms and consulting.

Products & services

Simcyp simulator

Model-informed drug development solutions

Customers & end markets

Pharmaceutical and biotechnology companies

Regulatory agencies

Market position

Certara is a niche leader in biosimulation and model-informed drug development within the health information services industry.

Demand drivers

Medium cyclicality

Demand is linked to pharmaceutical R&D spending, which can fluctuate with industry cycles and regulatory environments.